BioLineRx Ltd.
NASDAQ: BLRX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Philip A. Serlin
- Employees
- 28
- Headquarters
- Hevel Modi'in, Israel
- IPO year
- 2011
- Market cap
- $14.7M
- Website
- https://www.biolinerx.com
Loading BLRX…
Loading profile data…Frequently asked questions about BLRX
What does BioLineRx Ltd. (BLRX) do?
BioLineRx Ltd., an Israeli biopharmaceutical firm established in 2003 and based in Hevel Modi'in, focuses its clinical-stage development efforts primarily on oncology. Their leading investigational product, Motixafortide, a peptide, has successfully concluded pivotal Phase 3 clinical trials for mobilizing stem cells in autologous transplants, an...
Where does BLRX trade?
BioLineRx Ltd. (BLRX) trades on the NASDAQ Capital Market.
What sector is BLRX in?
BioLineRx Ltd. (BLRX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of BioLineRx Ltd.?
Philip A. Serlin is the chief executive officer of BioLineRx Ltd. (BLRX).
Where is BioLineRx Ltd. headquartered?
BioLineRx Ltd. is headquartered in Israel.
Does BLRX pay a dividend?
BioLineRx Ltd. (BLRX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BLRX go public?
BioLineRx Ltd. (BLRX) completed its initial public offering in 2011.
Is BLRX an ADR?
Yes — BLRX is an American Depositary Receipt; its underlying shares trade on a non-US exchange. BioLineRx Ltd. reporting and dividends follow the underlying issuer.